Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.
You may also be interested in...
Sandoz Continues Momentum From Omnitrope Decision With Momenta Partnership
Momenta’s characterization technology could facilitate manufacture of follow-on biologics.
Sandoz Continues Momentum From Omnitrope Decision With Momenta Partnership
Momenta’s characterization technology could facilitate manufacture of follow-on biologics.
Sandoz May Turn To Novartis Sales Force For Omnitrope Marketing
Sandoz' follow-on human growth hormone cleared FDA May 30, but the agancy asserts that the approval does not create a biosimilar regulatory pathway.